Data for "Surgical Debulking Modifies Notch Signaling and May Improve Vismodegib Effectiveness for Locally Advanced Basal Cell Carcinoma"
Smoothened (SMO) inhibitors, such as vismodegib, exhibit remarkable success in treating patients with locally advanced basal cell carcinoma (LaBCC). Yet, vismodegib efficacy is hindered by notable side effects, which often lead to treatment discontinuation and subsequent relapse in LaBCC patients. Prolonged remission was previously reported in patients with LaBCCs who underwent surgical debulking before starting vismodegib. Here, we enrolled four patients with LaBCC who underwent debulking followed by vismodegib therapy to assess their clinical outcomes and analyze the cutaneous molecular changes occurring as a result of surgical intervention. Following LaBCC debulking, patients underwent a punch biopsy of residual BCC tissue one week later. RT-qPCR analysis of 24 Notch and Wnt signaling-associated genes revealed elevated PTCH1, HEY2, LGR6, FZD2, LEF1, ALCAM, and RUNX1 expression in follow-up biopsies compared to patient-matched debulked tissue. Immunoblot and immunostaining further confirmed elevated Notch signaling in follow-up biopsy tissue compared to patient-matched debulked tumor tissue. Patients 1, 3, and 4 displayed a clinical response to debulking followed by vismodegib, while Patient 2 was lost to follow-up post-debulk. These findings suggest that surgical manipulation of LaBCCs is correlated with molecular alterations in signaling pathways associated with cellular reprogramming.
Citation
Files
Metadata
Work Title | Data for "Surgical Debulking Modifies Notch Signaling and May Improve Vismodegib Effectiveness for Locally Advanced Basal Cell Carcinoma" |
---|---|
Access | |
Creators |
|
Keyword |
|
License | CC BY 4.0 (Attribution) |
Work Type | Dataset |
Publication Date | June 5, 2024 |
Related URLs | |
Deposited | June 25, 2024 |
Versions
Analytics
Collections
This resource is currently not in any collection.